SpaceX's Historic IPO, Apple's iOS 27, and New Longevity Trials
This week's digest covers SpaceX's record-breaking IPO, Apple's iOS 27 release, the Pentagon's reclassification of Chinese tech firms, and new breakthroughs in longevity and antibiotic research.
Podcast В· 4 min
SpaceX Completes Record-Breaking $75B IPO
SpaceX has executed the largest IPO in history, raising $75 billion at a valuation of $1.77 trillion. The offering, which priced 555.6 million shares at $135 each, makes Elon Musk the world's first trillionaire on paper, with his stake valued at over $866 billion. The company reported $18.7 billion in revenue for 2025 with a loss of $4.9 billion, yet investors are betting on future projects like orbital data centers and Mars colonization. This valuation places SpaceX as the seventh most valuable U.S. company, surpassing Tesla, and signals a massive shift in capital allocation toward space-based infrastructure.
Google and SpaceX Strike $920M Monthly Compute Deal
Google has agreed to pay SpaceX $920 million per month for access to approximately 110,000 Nvidia GPU-powered compute units hosted in SpaceX data centers. This partnership highlights the growing demand for massive compute capacity to support AI development and the strategic role SpaceX is playing in providing infrastructure for tech giants. The deal underscores the convergence of space-based operations and terrestrial AI infrastructure needs.
Apple Recasts iOS 27 as Performance-Focused Update
Apple has unveiled iOS 27, positioning it as a cleanup and performance-focused release rather than a radical overhaul. The update introduces a transparency slider to adjust the controversial 'Liquid Glass' design elements, responding to user feedback. Performance improvements include 30% faster app launches and 70% faster photo loading. By extending support back to the iPhone 11, Apple is maintaining a large active user base, though the move suggests a strategic shift toward stability and optimization over aggressive obsolescence.
Tools for Humanity Initiates Layoffs Amid Regulatory Pressure
Tools for Humanity, the company behind the Worldcoin iris-scanning project, is cutting staff following revenue struggles and significant regulatory blowback. Despite a $2.5 billion valuation backed by major venture firms, the company has faced bans and privacy investigations in multiple countries, including South Korea. The layoffs highlight the challenges of scaling biometric-based crypto projects in a tightening regulatory environment, contrasting sharply with the successful IPO trajectory of other Altman-affiliated ventures like OpenAI.
David Sinclair Launches Human Trials for Age-Reversal Drug
Longevity scientist David Sinclair has announced human trials for SL-100, an oral drug designed to achieve whole-body rejuvenation through chemical reprogramming. The drug aims to mimic embryonic gene expression to reverse aging across multiple organs. Sinclair plans to use the trials to compete for the XPrize's $101 million age-reversal contest. However, the project faces significant skepticism from the scientific community, particularly due to the lack of published animal data and previous controversies surrounding Sinclair's research claims.
Researchers Discover Novel Superbug Killer in Soil
Scientists have identified manikomycin, a new antibiotic derived from a 75-year-old soil bacterium, which targets a previously unexploited ribosome site in bacteria. Published in Nature, the research shows that manikomycin effectively eliminates drug-resistant pathogens like E. coli and Klebsiella pneumoniae in laboratory settings. While the compound is currently a lead candidate rather than a finished drug due to stability issues in the bloodstream, it represents a significant breakthrough in the search for new mechanisms to combat the growing threat of antibiotic resistance.
Pentagon Labels Major Chinese Tech Firms as Military-Linked
The U.S. Pentagon has expanded its list of 'Chinese military companies' to include major consumer tech giants such as Alibaba, Baidu, and BYD. While the designation does not immediately impose sanctions, it restricts these companies from accessing U.S. defense contracts and research funding. This move significantly escalates the U.S.-China security standoff, effectively branding a broad swath of China's tech sector as potential national security threats and complicating investment and supply chain operations for these firms.